Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26807214 | 1.00 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL606825 | 1.00 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL32677703 | 1.00 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL28117691 | 0.90 | CYP19A1 (0.56) | CYP19A1CYP1B1 | |
| SCHEMBL1316417 | 0.82 | CYP19A1 (0.45) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL4448210 | 0.82 | CYP17A1 (0.46) | CYP19A1MEN1LMNASHBGSERPINA6 | |
| SCHEMBL1316415 | 0.82 | CYP19A1 (0.45) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL19818388 | 0.81 | CYP17A1 (0.65) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL29688903 | 0.81 | CYP17A1 (0.65) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL4448216 | 0.81 | CYP19A1 (0.61) | CYP19A1CYP1B1MEN1LMNASHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2667876-A2 | METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS | Harbor BioSciences, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| WO-2012083090-A2 | METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS | HARBOR BIOSCIENCES, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| US-20070099880-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-05-03 | — | — | US | claimed |
| EP-1689767-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051972-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | claimed |
| EP-2667876-A2 | METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS | Harbor BioSciences, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012083090-A2 | METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS | HARBOR BIOSCIENCES, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20080015173-A1 | Estrogen Receptor Modulators | MERCK & CO., INC. | 2008-01-17 | — | — | US | disclosed |
| US-20070203102-A1 | Estrogen Receptor Modulators | MERCK & CO., INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070105827-A1 | Estrogen receptor modulators | BLIZZARD TIMOTHY A | 2007-05-10 | — | — | US | disclosed |
| US-20070099880-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-05-03 | — | — | US | disclosed |
| EP-1773862-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1689767-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006081152-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006012333-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005051972-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105827-A1 | Estrogen receptor modulators | ESR2, ESR1, GPER1 | CYP19A1 27/4885CYP1B1 1619/4885MEN1 1403/4885 |
| US-20080015173-A1 | Estrogen Receptor Modulators | ESR2, GPER1, ESRRA | CYP19A1 34/4885CYP1B1 1812/4885MEN1 2361/4885 |
| US-20070203102-A1 | Estrogen Receptor Modulators | ESR2, GPER1, ESRRA | CYP19A1 34/4885CYP1B1 1812/4885MEN1 2361/4885 |
| US-20070099880-A1 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | CYP19A1 34/4885CYP1B1 1812/4885MEN1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.